Literature DB >> 18548253

Comments on the article "Targeted therapy in renal cell carcinoma" by J.-J. Patard et al.

Bernard Escudier.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18548253     DOI: 10.1007/s00345-008-0280-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  2 in total

1.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

2.  Targeted therapy in renal cell carcinoma.

Authors:  Jean-Jacques Patard; Damien Pouessel; Karim Bensalah; Stéphane Culine
Journal:  World J Urol       Date:  2008-02-12       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.